ONO Pharmaceutical Co (OPHLF) Income Statement
ONO Pharmaceutical Co Income Statement
Last quarter (Q3 2026), ONO Pharmaceutical Co's total revenue was $139.90B, an increase of 20.44% from the same quarter last year. In Q3, ONO Pharmaceutical Co's net income was $28.86B. See ONO Pharmaceutical Co’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|---|---|
| $ 486.87B | $ 515.78B | $ 502.67B | $ 447.19B | $ 361.36B | |
| $ 335.47B | $ 374.07B | $ 372.67B | $ 334.28B | $ 264.91B | |
| $ 272.08B | $ 270.73B | $ 209.10B | $ 181.99B | $ 150.00B | |
| Depreciation and Amortization | $ 26.89B | $ 37.75B | $ 18.14B | $ 17.45B | $ 17.72B |
| $ 87.86B | $ 133.94B | $ 181.98B | $ 161.11B | $ 122.82B | |
| $ 63.38B | $ 103.33B | $ 163.56B | $ 152.29B | $ 114.91B | |
| $ -4.06B | $ -10.68B | $ 173.00M | $ -8.76B | $ -9.89B | |
| $ 59.33B | $ 92.65B | $ 163.73B | $ 143.53B | $ 105.03B | |
| $ 50.05B | $ 69.77B | $ 127.98B | $ 112.72B | $ 80.52B | |
| Per Share Metrics | |||||
| Basic EPS | $ 106.55 | $ 148.49 | $ 266.61 | $ 230.85 | $ 162.19 |
| Diluted EPS | $ 106.41 | $ 148.42 | $ 266.57 | $ 230.79 | $ 162.16 |
| Weighted Average Shares Outstanding | 469.69M | 469.85M | 480.01M | 488.30M | 496.46M |
| Weighted Average Shares Outstanding (Diluted) | 469.77M | 469.97M | 480.04M | 488.35M | 496.53M |
Currency in JPY